Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: A systematic review and meta-analysis

Supportive Care in Cancer

Volumn 20, Issue 10, 2012, Pages 2523-2530

  Younis, Tallal ^a   Rayson, Daniel ^a   Thompson, Kara ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Adjuvant chemotherapy; Breast cancer; Docetaxel; Febrile neutropenia; G CSF; Prophylaxis; Supportive care

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

AGE DISTRIBUTION; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL PRACTICE; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; LENGTH OF STAY; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEVER; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEUTROPENIA; TAXOIDS;

EID: 84868483087     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1375-6     Document Type: Review

References (37)

1. Lyman GH, Rolston KVI (2010) How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract 6(3):149- 152
2. Smith TJ, Khatcheressian J, Lyman GH et al (2006) Update of ASCO practice guideline recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205 (Pubitemid 46638957)
3. Aapro MS, Bohlius J, Cameron DA et al (2011) For the European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8-32
4. Lathia N, Mittmann N, DeAngelis C et al (2010) Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 116(3):742-748
5. Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebocontrolled phase iii study. J Clin Oncol 23:1178-1184 (Pubitemid 46202274)
6. Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302- 2313 (Pubitemid 40740554)
7. Roche H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for nodepositive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24(36):5664-5671 (Pubitemid 46631307)
8. Jones SE, Savin MA, Holmes FA et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24(34):5381-5387 (Pubitemid 46623169)
9. Martin M, Lluch A, Segui M et al (2006) Toxicity and healthrelated quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5- fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17:1205-1212 (Pubitemid 44288210)
10. Soong D, Haj R, Leung M et al (2009) High rate of febrile neutropaenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide. J Clin Oncol 27:101-102
11. Takabatake D, Taira N, Hara F et al (2009) Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. Jpn J Clin Oncol 39(8):478-483
12. Myers R, Higgins B, Myers J et al (2009) Chemotherapy induced febrile neutropenia of docetaxel with cyclophosphamide(TC) for adjuvant therapy of breast cancer in the community-reality check. Cancer Res 69(24 Suppl), Abstract 2092
13. Chan A, Fu WH, Shih V et al (2011) Impact of colonystimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer 19(4):497-504, Epub 2010 Mar 17
14. Caley A, Bertelli G, Rolles M et al (2010) Adjuvant taxane chemotherapy is associated with a significant risk of febrile neutropenia. Eur J Cancer Suppl 8(3):10, Abstract 40
15. Vandenberg T, Younus J, Al-Khayyat S (2010) Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice - a retrospective analysis. Curr Oncol 17 (2):2-3
16. Santos FN, Cruz MR, Cezana L et al (2010) Hematologic toxicity with adjuvant docetaxel and cyclophosphamide in early breast cancer. J Clin Oncol 28, suppl; abstr e11081
17. McIlroy P, Lumsden G, Haslett K, Macpherson IR (2010) Docetaxel/ cyclophosphamide (TC) chemotherapy for early breast cancer: is primary G-CSF prophylaxis necessary? Cancer Res 70(24 Suppl), abstract P5-10-25
18. Tran M, Simmons CE, Haq R, Brezden CB (2010) A pragmatic review of adjuvant chemotherapy regimens in early-stage breast cancer - hematologic toxicities experienced in a single institution. Cancer Res 70(24 Suppl), abstract P5-10-24
19. Rayson D, Lutes S, Sellon M, et al. (2011) Population-based incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study. In: St. Gallen Breast Cancer Conference 2011 (16-19 March 2011); (Abstract P332) [available from http://www.poster-submission.com/search/ sresult]
20. Kotasek D (2011) Febrile neutropenia rates during docetaxel and cyclophosphamide (TC) adjuvant therapy in early breast cancer (EBC). J Clin Oncol 29, suppl; abstr 1101
21. Marinho FDS, Lopes MdSdS, Monteiro MMF, Gifoni M (2011) Incidence of febrile neutropenia with adjuvant docetaxel and cyclophosphamide in patients with early breast cancer. J Clin Oncol 29, suppl; abstr e11501
22. Ngamphaiboon N, Advani PP, O'Connor TL et al (2011) Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in patients with breast cancer: A retrospective analysis. J Clin Oncol 29, suppl; abstr 1134
23. Soni A, Brufsky A, Jankowitz RC et al (2011) Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a university-based breast oncology clinic. J Clin Oncol 29, suppl; abstr 9061
24. Ali Z, O'Reilly S, Zahoor T, Schofield P, Malik A. Experience of febrile neutropaenia and secondary G-CSF prophylaxis during FEC-D chemotherapy in Merseyside and Cheshire Cancer Network. In: National Cancer Research Institute (NCRI) Cancer Conference 2008; (Abstract B67) [available from http://www. ncri.org.uk/ncriconference/2008abstracts/abstracts/B67.htm]
25. Head J, Archer C, Harper-Wynne C, et al. Rates of neutropaenic sepsis with the use of adjuvant FEC100-Docetaxel (FEC100-T) chemotherapy in high-risk node-positive patients with early breast cancer; A UK perspective. In: National Cancer Research Institute (NCRI) Cancer Conference 2008; (Abstract B64) [available from http://www.ncri.org.uk/ncriconference/2008abstracts/abstracts/ B64.htm]
26. Gohil S, Sharma A, Harper-Wynne C. Comparison of rates of febrile neutropaenia using FEC100/Docetaxel100 chemotherapy in breast cancer patients with and without primary GCSF prophylaxis. In: National Cancer Research Institute (NCRI) Cancer Conference 2009; (Abstract B64) [available from http://www.ncri.org. uk/ncriconference/2009abstracts/abstracts/B75.htm]
27. Raza S, Welch S, Younus J (2009) Relative dose intensity delivered to patients with early breast cancer: Canadian experience. Curr Oncol 16(6):8-12
28. AlKhayyat S, Dent S, Verreault J et al (2009) Incidence of Febrile Neutropenia with Adjuvant FEC-D Therapy in Women with Early Stage Breast Cancer. Cancer Res 69(24 Suppl), Abstract 2087
29. Gerlier L, Lamotte M, Awada A et al (2010) The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma. BMC Cancer 10:642
30. Fraser J, Steele N, Al Zaman A, Yule A (2011) Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group. Eur J Cancer 47(2):215-220
31. Madarnas Y, Dent SF, Husain SF et al (2011) Real-world experience with adjuvant FEC-D chemotherapy in four Ontario regional cancer centres. Curr Oncol 18(3):119-125
32. Newcombe RG (1998) Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med 17:857-872 (Pubitemid 28185165)
33. Borenstein M, Hedges L, Higgins J, Rothstein H (2005) Comprehensive meta analysis. ver. 2. Biostat, Englewood
34. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558 (Pubitemid 34746062)
35. Sung L, Nathan PC, Alibhai SM et al (2007) Meta-analysis: effect of prophylactic hematopoietic colony stimulating factors on mortality and outcomes of infection. Ann Intern Med 147:400-411 (Pubitemid 351664541)
36. Bashir MO, Wu S (2011) Docetaxel-induced neutropenia and neutropenic fever in general and elderly patient population: a meta-analysis. J Clin Oncol 29, suppl; abstr e19729
37. Chan KK, Trudeau ME, Eisen A et al (2011) The costeffectiveness of primary prophylaxis with granulocyte colonystimulating factor in docetaxel-containing adjuvant chemotherapy in early breast cancer: the impact of risk of febrile neutropenia and its mortality. J Clin Oncol 29, suppl; abstr 6086